Bausch+Lomb Investor Conference Presentation Deck
Growth Driven by a Diversified Portfolio of Eye Care Products
63%
Vision Care
$1,747M
Nine Months as of
Sept. 30, 2022
Contact Lens
37%
BAUSCH + LOMB
Consumer
Durable, market-leading megabrands in
consumer health portfolio
Complete portfolio of contact lens modalities
and technologies
Scalable opportunity for future growth
54%
Surgical
$530M
Nine Months as of
Sept. 30, 2022
■ Implantables
27%
19%
Equipment
Consumables/Other
Extensive product suite for all
major procedures
Equipment platform drives demand
for significant portion of the portfolio:
consumables / implantables
Ophthalmic Pharmaceuticals
41%
U.S.
$495M
Nine Months as of
Sept. 30, 2022
59%
International
Broad portfolio in ophthalmology market
Portfolio breadth and depth of ~100 products,
with large commercial infrastructure
Expected new launches represent opportunity
for future growth
5View entire presentation